Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Lajos Géczi et al.|The Lancet Oncology|2021Cited by 645
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Johann S. de Bono, Nicolás Herranz et al.|European Urology|2020Cited by 118